OBJECTIVETo evaluate and improve the diagnosis and surgical treatment of the retroperitoneal fibrosis (RPF).

METHODSThe medical records of 26 patients with the RPF (21 men and 5 women with mean age 54 years) were analyzed retrospectively. They were been treated from January 1996 to May 2007. Fourteen cases received double-J inter-ureter drainage or pricking pyelostomy and 9 of 15 cases who received open surgery were performed bilateral ureterolysis with their ureters translocated intraperitoneally.

RESULTSFor masses in retroperitoneal space, the diagnostic rate of B mode ultrasonography, CT and MRI was 12% (3/26), 86% (18/21) and 57% (8/14) respectively. The patients were followed up from 1 to 106 months. After drained by double-J inter-ureter stent or pricking pyelostomy, the mean serum creatinine level decreased from 373.9 micromol/L to 157.1 micromol/L of 14 patients. Those patients who underwent ureterolysis with ureteral intraperitoneal translocation had good results and their mean serum creatinine level decreased from 171.0 micromol/L before operation to 139.6 micromol/L after operation. Four patients had normal B-ultrasound and intravenous urogram findings with at least 24 months of follow-up.

CONCLUSIONSCT scan has better accuracy for diagnosis of the RPF than B mode ultrasonography and MRI. Prompt and appropriate relief of urinary obstruction with surgical intervention can effectively protect the renal function in patients with the RPF, and the ureterolysis with ureteral intraperitoneal translocation is an effective surgical procedure to treat this disease.

Adult ; Aged ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Retroperitoneal Fibrosis ; diagnosis ; surgery ; Retrospective Studies ; Treatment Outcome

Objective To explore the effects of zedoary turmeric oil on proliferation and apoptosis of SW1463 cell line and the expression of Caspase-3,Bax and Bcl-2.Methods Volatile oil from Curcumae Rhizoma in Guizhou was extract by steam distillation,which was used to intervene SW1463 cells for 24,48 and 72 h at concentration of 40,80,120,160,200,240 and 280 mg/mL.MTT method was used to detect the inhibitory rate of zedoary turmeric oil on SW1463 cell proliferation.Effects of different concentrations of zedoary oil on apoptosis of SW1463 cells were observed by Giemsa staining.Western blotting was used to detect Capase-3,Bax and Bcl-2 protein expression.Results Zedoary turmeric oil inhibited the proliferation of SW1463 cells and showed a time dose correlation,and half maximal inhibitory concentration (IC50) of 24,48 and 72 h was 144.33,134.11 and 120.04 mg/L,respectively.Giemsa staining showed obvious morphological characteristics of apoptotic cells.Western blotting results showed that compared with control group,the expression of Caspase-3 and Bax in cells treated with zedoary turmeric oil for 24 h were significantly up-regulated (P ＜ 0.05),and the expression of Bcl-2 protein was significantly down-regulated (P ＜ 0.05).Conclusion Zedoary turmeric oil can obviously inhibit the proliferation of SW1463 cells and induce apoptosis,which may be related to the up-regulation of Caspase-3 and Bax protein expression and down-regulation of Bcl-2 protein expression.

OBJECTIVETo explore the method of predicting the stage of prostate cancer with serum prostate-specific antigen (PSA) and pathological grade.

METHODSOne hundred and eighty-seven patients were studied retrospectively with prostate cancer diagnosed by systemic biopsy in our hospital. The rank correlation analysis, rank sum test and stepwise discriminant multivariate analysis were used to assess the correlation of serum PSA level, ratio of free PSA to total PSA (FPSA/TPSA ratio) with Gleason score (GS) and stage.

RESULTSSerum PSA level increased with GS for prostate cancer patients (r = 0.369, P < 0.001). With increasing stage, serum PSA level and GS increased (r = 0.398, 0.530, P < 0.001). Overall, FPSA/TPSA ratio was not correlated with stage (P > 0.70), but a significant negative correlation was demonstrated between them when serum PSA < or = 10 microg/L (r = -0.600, P < 0.05). When serum PSA > 20 microg/L, 67% - 87% patients with prostate cancer may be stage C or D. The equation using serum PSA and GS to predict the stage of patients with prostate cancer was: x = -3.488 + 0.041 x PSA + 0.428 x GS.

CONCLUSIONSSerum PSA level is positively correlated with GS for prostate cancer patients. Serum PSA level and GS are positively correlated with stage. A negative correlation between FPSA/TPSA ratio and stage is demonstrated when serum PSA < or = 10 microg/L. The combination of serum PSA and GS may predict the stage of patients with prostate cancer.

Adult ; Aged ; Aged, 80 and over ; Humans ; Male ; Middle Aged ; Multivariate Analysis ; Neoplasm Staging ; methods ; Prostate-Specific Antigen ; blood ; Prostatic Neoplasms ; blood ; pathology ; ROC Curve ; Retrospective Studies ; Sensitivity and Specificity

OBJECTIVETo define changes in clusterin expression following short-term neoadjuvant hormone therapy (NHT) and its biological significance in prostate cancer tissues.

METHODSTwenty-six archival radical prostatectomy (RP) specimens without receiving NHT, 19 needle biopsies and corresponding 19 RP specimens following 3-month NHT, were subjected to immunohistochemical clusterin staining.

RESULTSStaining for clusterin was mainly found in cytoplasm and part of extracellular matrix. Clusterin expression was significantly greater in RP specimens with preoperative NHT (t = 2.91, P < 0.01); Needle biopsies obtained before NHT consistently demonstrated lower staining intensity (1.42 +/- 0.51) than corresponding RP specimens (2.16 +/- 0.60) following 3-month NHT (t = 7.10, P < 0.01).

CONCLUSIONSUpregulation of clusterin in part accounts for malignant progression of prostate cancer through its anti-apoptotic action following androgen withdrawal. These findings support that adjuvant therapy targeting clusterin may enhance androgen ablation therapy in advanced prostate cancer.

Aged ; Clusterin ; genetics ; metabolism ; Humans ; Immunohistochemistry ; Male ; Middle Aged ; Neoadjuvant Therapy ; methods ; Oligonucleotides, Antisense ; therapeutic use ; Prostatic Neoplasms ; metabolism ; pathology ; therapy